Quintiles is partnering with Samsung Group on a $266 million initiative to bring the South Korean conglomerate into the drug manufacturing business.
Durham, North Carolina-based Quintiles provides an array of services for pharmaceutical companes and it is the largest clinical research organization in the industry. Quintiles spokesman Phil Bridges said that the company’s involvement with Samsung is a $30 million stake in the effort.
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Bridges said Quintiles can help Samsung get into what for the South Korean conglomerate is a completely new market in life sciences. Besides holding a minority stake in Samsung’s biopharmaceuticals initiative, Quintiles will also offer Samsung its pharmaceuticals expertise. Quintiles has had a presence in South Korea since 2000 and currently employs about 100 people there.
“As part of the strategic partnership, Quintiles will provide clinical development and consulting services to Samsung as required,” Bridges said.
Samsung, a diversified company whose businesses include consumer electronics, insurance and shipbuilding, announced last year plans to add biopharmaceutical manufacturing to its portfolio. Samsung said that it plans for a South Korean factory that will produce biopharmaceutical drugs to treat cancer and arthritis. Ground breaking is scheduled for May and operations are expected to launch in April 2013.
Quintiles has established several partnerships with pharmaceutical companies, such as Eli Lilly (NYSE:LLY), that go beyond the traditional CRO role of providing outsourced pharmaceutical services. But Bridges said it is unusual for Quintiles to be working with a company such as Samsung that is not already a pharmaceuticals player. While Bridges would not say that this is the only partnership Quintiles has outside the life sciences space, he said the Samsung arrangement “is pretty unique for us.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
